CR2O is proud to announce today it will manage and further support the clinical and preclinical development of DYAI-100, Dyadic’s C1 produced SARS-CoV-2-S-RBD vaccine candidate. The first-in-human trial with DYAI-100...Read More
Dutch industry magazine Biotech NEWS and Life Sciences has profiled CR2O in their 2020 Winter edition. Biotech NEWS and Life Sciences is a national magazine reporting on trends and news within health...Read More
The EU Research and Innovation programme HORIZON 2020 has awarded a contract to a consortium that aims towards a next generation influenza vaccine to protect citizens worldwide (an EU-India collaboration)....Read More
The EU Research and Innovation programme HORIZON 2020 has awarded contract worth up to 6 million euro’s to consortium led by Amsterdam Medical Center under grant agreement No 634886. GLORIA...Read More
The EU Research and Innovation programme HORIZON 2020 has awarded a contract worth up to 3 million euro’s to a European consortium led by ErasmusMC in collaboration with Harbour Antibodies...Read More
As a result of the COVID-19 pandemic, CR2O has adapted its contingency plan aimed to guarantee the safety and well-being of patients, employees, clients and continuity of our services.By following...Read More
The EU Research and Innovation programme HORIZON 2020 has awarded a contract worth up to 6 million euro’s to a consortium led by Stiftung Tieraerztliche Hochschule Hannover (TiHo), aimed at...Read More
Wageningen Bioveterinary Research (WBVR), part of Wageningen University & Research, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new partnering agreement. With support from the European Union’s...Read More
CEPI awarded a program which is aimed at the manufacturing and stockpiling of clinical supplies of MVA-MERS-S and the concomitant clinical development to a stage where outbreak deployment readiness is...Read More
